Clovis Oncology Operating Income

Clovis Oncology (CLVS) currently reports a operating income of $-210M as of September 2022. That compares with $-230M in the prior-year period — up 11.1% year over year. Use the charts on this page to explore Clovis Oncology's operating income history and peer comparisons.

Clovis Oncology's operating income increased from $-230M to $-210M — a 11.1% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clovis Oncology reported $-210M in operating income as of September 2022. That compares with $-230M in the prior-year period — up 11.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Clovis Oncology, and consider following CLVS for alerts when major investors trade the stock.

Clovis Oncology is classified in the Healthcare sector. On operating income, it currently shows $-210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLVS with unrelated industries.